Refine by
Epitope Articles & Analysis: Older
47 news found
ELISA-based immunoassays are the gold standard for various aspects of vaccine bioanalysis, including quantification of antigenic epitopes, detection of contaminants, and determination of vaccine efficacy (e.g., vaccine titer and immunogenicity). ...
Computational design of antibodies such as AU-007 is a novel approach that Biolojic Design Founder and CEO Yanay Ofran has been developing for more than 10 years through an AI platform that uses computational biology and big data to guide the design of epitope-specific antibodies. His goal: to design antibodies that have a predetermined, desired effect on the function of a ...
Multiple vaccine types, such as DNA-, RNA-based formulations, subunits containing viral epitopes, adenovirus-based vectors and inactivated whole viruses are under development. ...
ByNuvonis
“We are thrilled to be issued this U.S. patent, which solidifies our position as a leader in AI-driven drug discovery, and whose claims guarantee broad coverage of our proprietary, epitope-steering antibody discovery engine,” said Martin Brenner, DVM. ...
Meanwhile, monoclonal antibodies have monovalent affinity and can only recognize the same epitope of an antigen. Monoclonal antibodies are commonly used as primary antibodies in immunoassays because of their ability to specifically bind a single epitope of an antigen. ...
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most ...
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most ...
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most ...
Highlights: ES004 recognizes pan-allele human SIRPα with high affinity ES004 binds to a unique epitope on the CD47 binding domain of SIRPα ES004 potently blocks CD47-SIRPα interaction and CD47 induced SIRPα signaling ES004 effectively potentiates pan-allelic macrophage phagocytosis of tumor cells ES004 has no negative impact on T cell activation ...
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most ...
Furthermore, Amerigo Scientific also offers three categories of antibodies for the detection of adeno-associated virus (AAV), namely 1) AAV capsid antibodies that specifically react with denatured AAV capsid protein, thereby recognizing linear epitopes of the viral capsid; 2) AAV particle antibodies that react specifically with intact AAV particles (i.e., empty and full capsids) ...
Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain detection) to broader models with applications across domains from sales and marketing to medical diagnostics. ...
The acquired assets include a patented system that uses artificial intelligencey (Al) to design 3D models of epitopes - which are the part of an antigen that is recognized by the immune system -to facilitate the creation of better antibody drug candidates (ADCs). ...
The AI Discovery Engine is unique as it is the only proprietary machine-learning platform of its kind to combine computational biology and 3D-modeling of epitopes for the identification and engineering of large-molecule drug candidates based upon subdominant, as well as conformational, epitopes that have proven hard to target using traditional ...
The acquired assets include: AI Drug Discovery Platform: A patented system that uses artificial intelligence (“AI”) to design 3D models of epitopes to facilitate the creation of better antibody drug candidates. Unlike other traditional and newer AI-driven methods of drug discovery that often focus upon dominant epitopes, the RubrYc Discovery Engine ...
PolyPEPI1018 has been developed using Treos’ proprietary PASCal computational tool to identify Personal EPItopes (PEPIs) that are likely to induce multiple tumor-specific T cell responses in a patient. ...
The company developed XMT-2056 leveraging a differentiated antibody that binds to a novel HER2 epitope, providing the opportunity, as demonstrated in preclinical studies, for treatment both as monotherapy and in combination with a variety of agents, including other anti-HER2 therapies. ...
The latter is a more conserved antigen that contains many T cell epitopes and allows for a broad protection against the variants under investigation. ...
Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: “We believe our proprietary GlyMab™ platform provides a powerful and versatile approach to generating novel antibody drug candidates that bind to sugar motifs, rather than peptide epitopes, found on the surface of glycosylated proteins and lipids that are implicated as drug targets in particular ...
ByScancell
With EXIS, Prellis is able to exploit fully-human immune responses for a variety of applications, including antibody discovery, immunogenicity screening, and T-cell epitope discovery, amongst others. Prellis further leverages its industry dominant bioprinting expertise for advanced tissue and disease models in combination with EXIS to accelerate and de-risk drug discovery of ...